Outlook Therapeutics, Inc.
OTLK
$0.64
$0.000.53%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -61.12M | -60.96M | -102.86M | -62.42M | -43.44M |
| Total Depreciation and Amortization | 104.00K | 119.60K | 118.30K | 117.00K | 116.10K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.56M | 5.30M | 49.78M | 4.06M | -20.48M |
| Change in Net Operating Assets | -4.70M | 8.49M | -2.84M | 6.41M | 7.37M |
| Cash from Operations | -56.15M | -47.05M | -55.80M | -51.83M | -56.43M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.10M | -- | -- | -- | -- |
| Cash from Investing | -2.10M | -- | -- | -- | -- |
| Total Debt Issued | 0.00 | 17.00M | 33.10M | 33.10M | 33.10M |
| Total Debt Repaid | -2.33M | -20.23M | -36.14M | -36.14M | -33.82M |
| Issuance of Common Stock | 65.83M | 50.92M | 62.27M | 48.48M | 34.59M |
| Repurchase of Common Stock | -- | -- | -- | -- | -115.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.91M | -448.00K | -448.00K | -448.00K | -448.00K |
| Cash from Financing | 60.60M | 47.24M | 58.78M | 44.99M | 33.31M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2.34M | 191.90K | 2.97M | -6.84M | -23.12M |